Neoadjuvant chemotherapy in operable breast cancer: The pros

Breast Care

Volumn 1, Issue 6, 2006, Pages 348-351

  Mamounas, E P ^a,b  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b Aultman Health Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAXANE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; AXILLARY LYMPH NODE; BREAST CANCER; CANCER PATIENT; CHEMOSENSITIVITY; DIAGNOSTIC ACCURACY; EDITORIAL; HUMAN; LYMPH NODE DISSECTION; PARTIAL MASTECTOMY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; THERAPY EFFECT; TREATMENT PLANNING; TREATMENT RESPONSE;

EID: 33845884593     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000097887     Document Type: Editorial

References (63)

1. Perloff M, Lesnick GJ: Chemotherapy before and after mastectomy in stage III breast cancer. Arch Surg 1882;117:879-81.
2. Schick P, Goodstein J, Moor J, et al.: Preoperative chemotherapy followed by mastectomy for locally advanced breast cancer. J Surg Oncol 1983;22:278-82.
3. Sorace RA, Bagley CS, Lichter AS, et al.: The management of nonmetastatic locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery. World J Surg 1985;9:775-85.
4. Skipper HE: Kinetics of mammary tumor cell growth and implications for therapy. Cancer 1971;28:1479-99.
5. Goldie JH, Coldman AJ: A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63:1727-33.
6. Gunduz N, Fisher B, Saffer EA: Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res 1979;39:3861-5.
7. Fisher B, Gunduz N, Saffer EA: Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 1983;43:1488-92.
8. Fisher B, Redmond C, Poisson R, et al.: Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1989;320:822-8.
9. Fisher B, Anderson S, Redmond CK, et al.: Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1995;333:1456-61.
10. Veronesi U, Saccozzi R, Del Vecchio M, et al.: Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med 1981;305:6-11.
11. Fisher B, Anderson S, Bryant J, et al.: Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002;347:1233-41.
12. Veronesi U, Cascinelli N, Mariani L, et al.: Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002;347:1227-32.
13. Group EBCTC: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 1992;339:71-85.
14. Group EBCTC: Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;352:930-42.
15. Jacquillat C, Weil M, Baillet F, et al.: Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 1990;66:119-29.
16. Bonadonna G, Veronesi U, Brambilla C, et al.: Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 1990;82:1539-45.
17. Tubiana-Hulin M, Malek M, Brifford M, et al.: Preoperative chemotherapy of operable breast cancer (stage IIIA). Prognostic factors of distant recurrence. Eur J Cancer 1993;29A:S76 (#391).
18. Belembaogo E, Feillel V, Chollet P, et al.: Neoadjuvant chemotherapy in 126 operable breast cancers. Eur J Cancer 1992;28A:896-900.
19. Smith IE, Jones AL, O'Brien ME, et al.: Primary medical (neo-adjuvant) chemotherapy for operable breast cancer. Eur J Cancer 1993;29A:1796-9.
20. Chollet P, Charrier S, Brain E, et al.: Clinical and pathological response to primary chemotherapy in operable breast cancer. Eur J Cancer 1997;33:862-6.
21. Gradishar WJ: Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer. Oncology (Huntingt) 1997;11:15-8.
22. Mauriac L, Durand M, Avril A, et al.: Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol 1991;2:347-54.
23. Scholl SM, Fourquet A, Asselain B, et al.: Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 1994;30A:645-52.
24. Scholl SM, Pierga JY, Asselain B, et al.: Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer 1995;31A:1969-75.
25. Powles TJ, Hickish TF, Makris A, et al.: Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 1995;13:547-52.
26. Makris A, Powles TJ, Ashley SE, et al.: A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 1998;9:1179-84.
27. Fisher B, Brown A, Mamounas E, et al.: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483-93.
28. Fisher B, Bryant J, Wolmark N, et al.: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-85.
29. Wolmark N, Wang J, Mamounas E, et al.: Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr:2001;96-102.
30. van der Hage JA, van de Velde CJ, Julien JP, et al.: Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001;19:4224-37. Gianni L, Baselga J, Eirmann W, et al.: European Cooperative Trial in Operable Breast Cancer (ECTO): Improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF). J Clin Oncol 2005;23:7S, abstr 513.
31. Bear HD, Anderson S, Brown A, et al.: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003;21:4165-74.
32. Gianni L BJ, Eiermann W, et al..: First report of the European Cooperative Trial in operable breast cancer (ECTO): effect of primary systemic therapy. Proc Am Soc Clin Oncol 2002;21:34a, abstr 132.
33. Breslin TM, Cohen L, Sahin A, et al.: Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2000;18:3480-6.
34. Nason KS, Anderson BO, Byrd DR, et al.: Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer 2000;89:2187-94.
35. Julian TB, Patel N, Dusi D, et al.: Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer. Am J Surg 2001;182:407-10.
36. Stearns V, Ewing CA, Slack R, et al.: Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol 2002;9:235-42.
37. Fernandez A, Cortes M, Benito E, et al.: Gamma probe sentinel node localization and biopsy in breast cancer patients treated with a neoadjuvant chemotherapy scheme. Nucl Med Commun 2001;22:361-6.
38. Haid A, Tausch C, Lang A, et al.: Is sentinel lymph node biopsy reliable and indicated after preoperative chemotherapy in patients with breast carcinoma? Cancer 2001;92:1080-4.
39. Miller AR, Thomason VE, Yeh IT, et al.: Analysis of sentinel lymph node mapping with immediate pathologic review in patients receiving preoperative chemotherapy for breast carcinoma. Ann Surg Oncol 2002;9:243-7.
40. Reitsamer R, Peintinger F, Rettenbacher L, et al.: Sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy. J Surg Oncol 2003;84:63-7.
41. Brady EW: Sentinel lymph node mapping following neoadjuvant chemotherapy for breast cancer. Breast J 2002;8:97-100.
42. Schwartz GF, Meltzer AJ: Accuracy of axillary sentinel lymph node biopsy following neoadjuvant (induction) chemotherapy for carcinoma of the breast. Breast J 2003;9:374-9.
43. Balch GC, Mithani SK, Richards KR, et al.: Lymphatic mapping and sentinel lymphadenectomy after preoperative therapy for stage II and III breast cancer. Ann Surg Oncol 2003;10:616-21.
44. Piato JR, Barros AC, Pincerato KM, et al.: Sentinel lymph node biopsy in breast cancer after neoadjuvant chemotherapy. A pilot study. Eur J Surg Oncol 2003;29:118-20.
45. Aihara T, Munakata S, Morino H, et al.: Feasibility of sentinel node biopsy for breast cancer after neoadjuvant endocrine therapy: a pilot study. J Surg Oncol 2004;85:77-81.
46. Mamounas EP: Sentinel lymph node biopsy after neoadjuvant systemic therapy. Surg Clin North Am 2003;83:931-42.
47. Mamounas EP, Brown A, Anderson S, et al.: Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: Results from National Surgical Adjuvant Breast and Bowel Prolect Protocol B-27. J Clin Oncol 2005;23:2694-2702.
48. O'Hea BJ, Hill AD, El-Shirbiny AM, et al.: Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg 1998;186:423-7.
49. McMasters KM, Tuttle TM, Carlson DJ, et al.: Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol 2000;18:2560-6.
50. Krag DN, Weaver DL, Alex JC, et al.: Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993;2:335-9; discussion 340.
51. Giuliano AE, Kirgan DM, Guenther JM, et al.: Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994;220:391-8; discussion 398-401.
52. Bear HD, Anderson S, Smith RE, et al.: Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006;24:2019-27.
53. Buzdar AU, Ibrahim NK, Francis D, et al.: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:3676-85.
54. Fisher B, Mamounas EP: Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer. J Clin Oncol 1995;13:537-40.
55. Smith IC, Heys SD, Hutcheon AW, et al.: Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002;20:1456-66.
56. Thomas E, Holmes FA, Smith, TL, et al.: The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol 2004;22:2294-2302.
57. von Minckwitz G, Raab G, Blohmer JU, et al.: Primary chemotherapy adapted on in-vivo-chemosensitivity in patients with primary breast cancer. The pilot GEPARTRIO study. Proc Am Soc Clin Oncol 2003;22:22, abstr 85.
58. Ayers M, Symmans WF, Stec J, et al.: Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004;22:2284-93.
59. Thuerigen O, Scneeweiss A, Toedt G, et al.: Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J Clin Oncol 2006;24:1839-45.
60. Gianni L, Zambetti M, Clark K, et al.: Gene expression
61. profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005;23:7265-77.
62. Paik S, Tang G, Shak S, et al.: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-34.
63. Chang JC, Wooten EC, Tsimelzon A, et al.: Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 2005;23:1169-77.